دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial
Ko Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, Takenori Domei, Masanobu Ohya, Manabu Ogita, Kensuke Takagi, Hirohiko Suzuki, Akira Nikaido, Mitsuru Ishii, Shinya Fujii, Masahiro Natsuaki, Satoshi Yasuda, Takeo Kaneko, Takashi Tamura, Toshihiro Tamura, Mitsuru Abe, Kazuya Kawai, Koichi Nakao, Kenji Ando, Kengo Tanabe, Yuji Ikari, Keiichi Igarashi Hanaoka, Yoshihiro Morino, Ken Kozuma, Kazushige Kadota, Yutaka Furukawa, Yoshihisa Nakagawa, Takeshi Kimura and on behalf of the STOPDAPT-2 Investigators
doi : 10.1161/CIRCINTERVENTIONS.120.010384
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010384
Safety and efficacy of clopidogrel monotherapy after very short dual antiplatelet therapy (DAPT) is uncertain in patients undergoing complex percutaneous coronary intervention (PCI).
Early P2Y12 Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin?
Carlo Briguori
doi : 10.1161/CIRCINTERVENTIONS.121.010880
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010880
Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial
Justin Cole, Nay Htun, Robert Lew, Mark Freilich, Stephen Quinn, Jamie Layland
doi : 10.1161/CIRCINTERVENTIONS.120.009992
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e009992
Periprocedural myocardial infarction and injury (PM-injury) are the most common complications of percutaneous coronary intervention (PCI) and are associated with future adverse cardiac events. Inflammation plays a pivotal role in the development of PM-injury. In this randomized pilot trial, we assessed the effect of an anti-inflammatory medication colchicine on periprocedural myocardial injury.
Immediate Compared With Delayed Percutaneous Coronary Intervention for Patients With ST-Segment–Elevation Myocardial Infarction Presenting ?12 Hours After Symptom Onset Is Not Associated With Improved Clinical Outcome
You-Jeong Ki, Jeehoon Kang, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Myeong-Chan Cho, Chong-Jin Kim, Youngkeun Ahn, Myung Ho Jeong, Jung-Kyu Han, Hyo-Soo Kim and on behalf of investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH)
doi : 10.1161/CIRCINTERVENTIONS.120.009863
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e009863
The role of immediate percutaneous coronary intervention (PCI; door-to-balloon time ?90 minutes) in patients with ST-segment–elevation myocardial infarction who present ?12 hours after symptom onset is still obscure. We sought to explore the clinical outcomes of immediate PCI in patients with ST-segment–elevation myocardial infarction depending on presentation time.
Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality
Tsuyoshi Kaneko, Raj R. Makkar, Amar Krishnaswami, James Hermiller, Adam Greenbaum, Vasilis Babaliaros, Pinak B. Shah, Stephen H. Bailey, Vinnie Bapat, Samir Kapadia, Amr E. Abbas
doi : 10.1161/CIRCINTERVENTIONS.120.010288
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010288
The use of valve-in-valve–transcatheter aortic valve replacement (VIV-TAVR) in degenerated aortic bioprosthesis has been increasing, but the Food and Drug Administration approval is limited to high-risk patients. We analyzed the real-world experience of SAPIEN 3 VIV-TAVR, especially in lower-risk patients, based on the Society of Thoracic Surgeons (STS) score.
Should Transcatheter Aortic Valve Replacement Become the Standard of Care for the Treatment of Failed Surgical Bioprosthetic Valves?
Josep Rodés-Cabau, Alberto Alperi, Philippe Pibarot
doi : 10.1161/CIRCINTERVENTIONS.121.010883
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010883
BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction
Jaffar M. Khan, Adam B. Greenbaum, Vasilis C. Babaliaros, Danny Dvir, Mark Reisman, James M. McCabe, Lowell Satler, Ron Waksman, Marvin H. Eng, Gaetano Paone, Marcus Y. Chen, Christopher G. Bruce, Annette M. Stine, Xin Tian, Toby Rogers, Robert J. Lederman
doi : 10.1161/CIRCINTERVENTIONS.120.010238
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010238
Coronary artery obstruction is a rare, devastating complication of transcatheter aortic valve replacement. Transcatheter electrosurgical aortic leaflet laceration (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction [BASILICA]) is a novel technique to prevent coronary artery obstruction. We report the 1-year outcomes of the BASILICA trial. Primary end points of 30-day success and safety have been reported previously.
Aspirin Versus Clopidogrel as Single Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry
Yusuke Kobari, Taku Inohara, Tetsuya Saito, Nobuhiro Yoshijima, Makoto Tanaka, Hikaru Tsuruta, Fumiaki Yashima, Hideyuki Shimizu, Keiichi Fukuda, Toru Naganuma, Kazuki Mizutani, Masahiro Yamawaki, Norio Tada, Futoshi Yamanaka, Shinichi Shirai, Minoru Tabata, Hiroshi Ueno, Kensuke Takagi, Yusuke Watanabe, Masanori Yamamoto, Kentaro Hayashida
doi : 10.1161/CIRCINTERVENTIONS.120.010097
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010097
Current guidelines recommend dual antiplatelet therapy for the first 1 to 6 months after transcatheter aortic valve replacement (TAVR); however, recent studies have reported better outcomes with single antiplatelet therapy than with dual antiplatelet therapy in the occurrence of bleeding events, while not increasing thrombotic events. However, no data exist about optimal single antiplatelet therapy following TAVR.
Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Aortic Stenosis in England
Glen P. Martin, Nick Curzen, Andrew T. Goodwin, James Nolan, Lognathen Balacumaraswami, Peter F. Ludman, Evangelos Kontopantelis, Jianhua Wu, Chris P. Gale, Mark A. de Belder, Mamas A. Mamas
doi : 10.1161/CIRCINTERVENTIONS.120.010413
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010413
Aortic stenosis requires timely treatment with either surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). This study aimed to investigate the indirect impact of coronavirus disease 2019 (COVID-19) on national SAVR and TAVR activity and outcomes.
Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry
Alexander Sedaghat, Vivian Vij, Baravan Al-Kassou, Steffen Gloekler, Roberto Galea, Monika Fürholz, Bernhard Meier, Marco Valgimigli, Gilles O’Hara, Dabit Arzamendi, Victor Agudelo, Lluis Asmarats, Xavier Freixa, Eduardo Flores-Umanzor, Ole De Backer, Lars S?ndergaard, Luis Nombela-Franco, Angela McInerney, Kaspar Korsholm, Jens Erik Nielsen-Kudsk, Shazia Afzal, Tobias Zeus, Felix Operhalski, Boris Schmidt, Gilles Montalescot, Paul Guedeney, Xavier Iriart, Noelie Miton, Jacqueline Saw, Thomas Gilhofer, Laurent Fauchier, Egzon Veliqi, Felix Meincke, Nils Petri, Peter Nordbeck, Szymon Rycerz, Dmitrii Ognerubov, Evgeny Merkulov, Ignacio Cruz-Gonz?lez, Rocio Gonzalez-Ferreiro, Deepak L. Bhatt, Alessandra Laricchia, Antonio Mangieri, Heyder Omran, Jan Wilko Schrickel, Josep Rodes-Cabau, Georg Nickenig
doi : 10.1161/CIRCINTERVENTIONS.120.010195
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010195
Left atrial appendage closure is an established therapy in patients with atrial fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to adverse events. As data on DRT characteristics, outcome, and treatment regimen are scarce, we aimed to assess these questions in a multicenter approach.
RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results
Marco Ferrone, Alaide Chieffo, Saud A. Khawaja, Miguel Moncada, Antonio Colombo, Azeem Latib, Giovanni Esposito, Eugenio Stabile, Marisa Avvedimento, Francesco Bedogni, Luca Testa, Juan Andres Delgado, Camilo Arana, Boris Vesga, Bernardo Cortese, Akiko Mahera, Juan F. Granada
doi : 10.1161/CIRCINTERVENTIONS.120.010013
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010013
Calcium Modification Techniques in Complex Percutaneous Coronary Intervention
Mohammed Shah, Osman Najam, Ravinay Bhindi, Kalpa De Silva
doi : 10.1161/CIRCINTERVENTIONS.120.009870
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e009870
Percutaneous coronary intervention is the most common mode of revascularization and is increasingly undertaken in high-risk subsets, including the elderly. The presence of coronary artery calcification is increasingly observed and significantly limits technical success. The mechanisms for this are multi-factorial, including increased arterial wall stiffness and impaired delivery of devices, leading to suboptimal stent delivery, deployment, and expansion which are harbingers for increased risk of in-stent restenosis and stent thrombosis. Although conventional balloon pretreatment techniques aim to mitigate this risk by modifying the lesion before stent placement, many lesions remain resistant to conventional strategies, due to the severity of calcification. There have been several substantial technological advancements in calcium modification methods in recent years, which have allowed improved procedural success with low periprocedural complication rates. This review will summarize the current adjunctive modification technologies that can be employed to improve technical outcomes in percutaneous coronary intervention in calcific disease and the evidence supporting these tools.
To Vent or Not to Vent: A Loaded Question During Venoarterial Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock
Pankaj Jain, Michael Salama, Kay Everett, Lara Reyelt, Navin K. Kapur
doi : 10.1161/CIRCINTERVENTIONS.121.010537
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 5: e010537
